<DOC>
<DOCNO>
EP-0000100
</DOCNO>
<TEXT>
<DATE>
19781220
</DATE>
<IPC-CLASSIFICATIONS>
<main>C07D-501/36</main> C07D-257/04 A61P-31/00 A61K-31/545 C07D-257/00 C07D-501/36 A61K-31/546 C07D-501/00 A61P-31/04 
</IPC-CLASSIFICATIONS>
<TITLE>
7-acylamino-3-(1-(2-sulfamoylaminoethyl)-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acids, a process for their preparation and compositions containing them.
</TITLE>
<APPLICANT>
smithkline corpus<sep>smithkline corporation<sep>smithkline beckman corporationp.o. box 7929 1 franklin plazaphiladelphia pennsylvania 19101us<sep>smithkline beckman corporation<sep>
</APPLICANT>
<INVENTOR>
berges david alan<sep>berges,david alan<sep>berges,david alan18 buckwalter roadphoenixville, pennsylvania 19460us<sep>berges,david alan<sep>berges,david alan18 buckwalter roadphoenixville, pennsylvania 19460us<sep>
</INVENTOR>
<ABSTRACT>
7-acyl-3-cephem -4-carboxylic acids, process for their  preparation and compositions containing them.   cephalosperins with the formula:    in which r represents a pharmaceutically acceptable acyl  group known to be utility as a substituent on the 7-amino  group in cephalosporins or on the 6-amino group in penicillins  have antibacterial activity.  the compounds are prepared  by displacement of an acetyl group from a 3-acetoxymethyl  group of an appropriately substituted cephalosporin or  7-amino cephalosporin with 1-(2- sulfamidoethyl)  1,4-dihydro-5h-tetrazole-5-thione, and if desired introducing  a required 7-acyl group.  
</ABSTRACT>
</TEXT>
</DOC>
